May 15, 2024
FogPharma and ARTBIO collaborate to co-develop new cancer therapies
FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.